Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Padcev (enfortumab vedotin ADC by Year
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. reported YoY (%) (%)
Pfizer Padcev (enfortumab vedotin ADC: 22.0% in FY2025.
Latest, FY2025
22.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“|| Padcev | 1,940 | 1,588 | 22% | 22% | 1,902 | 1,561 | 22% | 38 | 27 | 42% | 43%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.